Health Care Delivery

According to the researchers of the study, managing patients with hidradenitis suppurativa holistically may help reduce the burden of their disease.

Incidence of chronic rhinosinusitis (CRS) was associated with a higher rate of current and past proton pump inhibitor (PPI) use, in which elevated risk of PPI use and prescription duration were only found in those with CRS who did not have nasal polyps.

Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at outcomes for specific races, age groups or genders, said Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center.

The study, based on a case series in Japan, found the risk of grade 2 or above chemoradiation increased when durvalumab was started within 14 days of the final thoracic radiotherapy treatment.

The new trial was the first to investigate outcomes among a patient population living with HIV (PLWH) who were treated for anal precancerous growths, or high-grade squamous intraepithelial lesions.

Investigators said the benefits appeared relatively early in treatment for many patients and persisted throughout the study period.

Sex and age were associated with clinical characteristics of geriatric psoriasis, including type and location of disease, therapeutic considerations, and risk of comorbid nail involvement and psoriatic arthritis.

A single-center analysis of more than 30 years of data shows rates of preterm births and preeclampsia remained stable

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgery-naive or whose symptoms recur after endoscopic sinus surgery exhibited similarly significant benefits in quality of life (QOL) and symptom burden when given an exhalation system with fluticasone.

The FDA determined that the 3-dose Pfizer COVID-19 vaccine worked in children aged 6 months through 4 years; the bipartisan Senate gun deal will focuses on mental health; the pandemic has other viruses acting mysteriously, with children diagnosed with respiratory viruses in May and June.

Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic syndromes (MDS) and the applicability of a novel scoring system, presented during her plenary session at EHA2022, that aims to improve and refine MDS risk estimation.

John Mascarenhas, MD, director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, spoke on preliminary data findings of the phase 2 MANIFEST study investigating the efficacy and safety profile of pelabresib, ruxolitinib combination therapy in JAK inhibitor-naive patients with myelofibrosis and those with suboptimal response to ruxolitinib monotherapy.

The study suggests standardized uptake values may be a useful marker to predict treatment response and prognosis in lung adenocarcinoma.

Mandy Lauw, MD, PhD, physician scientist and chair of the YoungEHA committee, discussed the content presented at the YoungEHA Research Meeting at the 2022 European Hematology Association (EHA) Congress and core themes of the session she cochaired on the ethics of artificial intelligence (AI) and science in hematology.

Swaminathan P. Iyer, MD, of the University of Texas MD Anderson Cancer Center, explains the mechanism of action and efficacy/safety observed in phase 1 results of CTX130, a CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy, in the treatment of relapsed/refractory T-cell lymphoma.

The investigators cautioned, however, that the factors identified had only modest predictive power.

Amanda Ely is CEO of the Children’s HIV Association (CHIVA), an organization that provides support to children living with HIV in the United Kingdom and Ireland and their families.

Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, explains findings of his abstract at EHA2022 showing the impact of Australia’s pharmaceuticals benefit scheme on the rise of Bruton tyrosine kinase (BTK) inhibitor prescriptions for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL), as well as reasons behind the decrease in fludarabine, cyclophosphamide, and rituximab combination therapy usage for first-line CLL.

The results, say the study researchers, offer new insights into patient experiences during spinal muscular atrophy (SMA) clinical trials

A systematic review and meta-analysis found no clear advantage for automated red cell exchange.

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center and University of Washington, discussed positive health-related quality of life (HRQOL) findings of the SEQUOIA trial investigating zanubrutinib vs bendamustine/rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Study data are mixed, but some evidence suggests the administration of vitamin D may work as a low-risk prophylactic against graft-versus-host disease (GVHD).

A new model may be able to better identify which patients will respond to immunotherapy.

This new study, which the authors claim is the first to do so, investigated the relationship between COVID-19 vaccination status and survival outcomes among individuals with heart failure.

The study, based on 33 years of data, also explored auto-antibody production in the rare patient group.

Findings presented at the 82nd Scientific Sessions of the American Diabetes Association support the safety and efficacy of open-source automated insulin delivery (AID) systems among children and adults living with type 1 diabetes (T1D).

Ashok Subramanian, MBA, founder and chief executive officer, Centivo, speaks on the limitations of traditional employer-based health benefit plans in the pursuit of value-based care and what employers should consider in designing these incentives on a community level.

Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with incidence of eosinophilia not shown to reduce efficacy of the biologic.

The Federal Trade Commission (FTC) launched an inquiry into the practices of pharmacy benefit managers; FDA advisers overwhelmingly support approval of Novavax, a new COVID-19 vaccine; drug prices soar to 20% annual inflation.

This article presents a single-organization qualitative case description of the perspectives of patients with high-need, high-cost illnesses who participated in care management programs.